Showing results (141-150 of 427) with videos related to
Sort By:
Pageof 43
Acupuncture in Medicine : Journal of the British Medical Acupuncture Society|June 21, 2011
A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedemaBarrie R Cassileth, Kimberly J Van Zee, Yi Chan, et al.Cancer|November 17, 2011
Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancerConleth G Murphy, Divya Mallam, Samantha Stein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancerShanu Modi, Katherine S Panageas, Elaine T Duck, et al.Cancer Research|May 19, 2006
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanismKotha Subbaramaiah, Louise R Howe, Elisa R Port, et al.Journal of Lipid Research|April 6, 2016
Exocytosis of macrophage lysosomes leads to digestion of apoptotic adipocytes and foam cell formationAbigail S Haka, Valéria C Barbosa-Lorenzi, Hyuek Jong Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1995
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancerA D Seidman, A Tiersten, C Hudis, et al.Breast Cancer Research and Treatment|October 8, 2017
Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impactDavid B Page, Hannah Wen, Edi Brogi, et al.Breast Cancer Research and Treatment|July 16, 2017
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancerAnthony F Yu, Roy B Mukku, Shivani Verma, et al.The Oncologist|January 4, 2019
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-upRui Wang, Lillian M Smyth, Neil Iyengar, et al.Seminars in Oncology|December 1, 1995
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodesC A Hudis, A D Seidman, J Baselga, et al.Pageof 43